低分子肝素在晚期非小细胞肺癌抗凝治疗中对生存预后的影响

The effect of low molecular weight heparin on the survival and prognosis of patients with advanced non-small cell lung cancer treated by anticoagulation

目的:探讨低分子肝素治疗晚期非小细胞肺癌预防性抗凝中的临床疗效及对患者生活质量的改善作用.方法:2018年4月-2019年2月收治中晚期非小细胞肺癌患者90例,随机分为两组.对照组使用常规疗法;治疗组在常规疗法基础上加用低分子肝素.比较两组临床疗效改善程度及生活质量变化.结果:治疗组临床抗凝标志物指标水平及生活质量改善情况优于对照组,治疗组不良反应发生率明显低于对照组,差异均有统计学意义(P<0.05).结论:低分子肝素治疗晚期非小细胞肺癌,其对相关标志物有明显改善效果,可提高患者生活质量.

Objective:To explore the clinical effect of low molecular weight heparin in the treatment of prophylactic anticoagulation of advanced non-small cell lung cancer and the improvement of patients'quality of life.Methods:90 patients with advanced non-small cell lung cancer were selected from April 2018 to February 2019,they were randomly divided into the two groups.The control group was treated with conventional therapy,the treatment group was treated with low molecular weight heparin on the basis of conventional therapy.The improvement degree and quality of life of the two groups were compared.Results:The improvement of clinical anticoagulant markers and quality of life in the treatment group was better than that in the control group,the incidence of adverse reactions in the treatment group was significantly lower than that in the control group,the differences were statistically significant(P<0.05).Conclusion:Low molecular weight heparin has significantly improved the related markers in the treatment of advanced non-small cell lung cancer and can improve the quality of life.